22nd Century Group (NASDAQ:XXII) Stock Price Down 3.2% – Should You Sell?

22nd Century Group, Inc (NASDAQ:XXII)’s stock price fell 3.2% during mid-day trading on Tuesday . The stock traded as low as $2.05 and last traded at $2.14. 22,998 shares changed hands during trading, a decline of 59% from the average session volume of 56,738 shares. The stock had previously closed at $2.21.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 22nd Century Group in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock currently has an average rating of “Sell”.

22nd Century Group Trading Down 16.6%

The company has a fifty day simple moving average of $3.47 and a two-hundred day simple moving average of $11.16. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.42 and a quick ratio of 1.83. The company has a market capitalization of $1.23 million, a P/E ratio of 0.00 and a beta of 1.12.

Hedge Funds Weigh In On 22nd Century Group

An institutional investor recently bought a new position in 22nd Century Group stock. Geode Capital Management LLC purchased a new stake in 22nd Century Group, Inc (NASDAQ:XXII) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 46,491 shares of the biotechnology company’s stock, valued at approximately $36,000. Geode Capital Management LLC owned about 9.12% of 22nd Century Group as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 18.06% of the company’s stock.

22nd Century Group Company Profile

22nd Century Group, Inc, founded in 1998 and headquartered in New York, is a plant biotechnology company that applies proprietary breeding and gene modulation technologies to tobacco, hemp and related plant species. The company’s core mission is to develop and commercialize plant-based solutions that address public health, consumer wellness and agronomic needs. Its flagship reduced nicotine tobacco platform is engineered to deliver significantly lower levels of nicotine than conventional tobacco products while retaining the sensory characteristics sought by adult smokers.

Through its branded reduced nicotine tobacco products, marketed under the NEXT Generation™ portfolio, and its GenCanna® subsidiary focused on hemp cultivation and cannabinoid extraction, 22nd Century serves both commercial markets and contract research clients.